Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Ingredion Incorporated reported second quarter 2026 results that were broadly consistent with market expectations, marked by modest net sales growth but a decline in adjusted operating income.</li><li>The company’s net sales increased by 1% to $1.85 billion, primarily driven by growth in its Texture & Healthful Solutions segment, which posted a 5% rise in net sales and 7% increase in sales volume.</li><li>This segment achieved its second highest quarterly operating income ever, underpinned by strong customer innovation in healthful, clean-label, and protein- and fiber-fortification product categories, despite inflationary pressures such as rising tapioca costs.</li></ul>

Ingredion Incorporated reported second quarter 2026 results that were broadly consistent with market expectations, marked by modest net sales growth but a decline in adjusted operating income.The company’s net sales increased by 1% to $1.85 billion, primarily driven by growth in its Texture & Healthful Solutions segment, which posted a 5% rise in net sales and 7% increase in sales volume.This segment achieved its second highest quarterly operating income ever, underpinned by strong customer innovation in healthful, clean-label, and protein- and fiber-fortification product categories, despite inflationary pressures such as rising tapioca costs.

Ingredion’s Big Break — Could Tate & Lyle Supercharge Its Solutions Business?

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Ingredion is strategically shifting its portfolio towards higher-margin, value-added specialty ingredients, exemplified by the pending acquisition of Tate &amp; Lyle and the recent purchase of Benicaros. This move positions the company to capitalize on growing consumer demand for clean-label, health-focused, and plant-based products.</li>
  <li>The company demonstrates a solid financial profile with consistent cash flow generation and a commitment to shareholder returns through dividends and share buybacks. However, recent operational issues at a key U.S. facility and underperformance in certain geographic segments have introduced near-term headwinds.</li>
  <li>Valuation appears attractive relative to peers, with a lower P/E and EV/EBITDA multiples. The successful integration of acquisitions and resolution of operational challenges are key catalysts for realizing potential upside.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Ingredion is strategically shifting its portfolio towards higher-margin, value-added specialty ingredients, exemplified by the pending acquisition of Tate &amp; Lyle and the recent purchase of Benicaros. This move positions the company to capitalize on growing consumer demand for clean-label, health-focused, and plant-based products.
  The company demonstrates a solid financial profile with consistent cash flow generation and a commitment to shareholder returns through dividends and share buybacks. However, recent operational issues at a key U.S. facility and underperformance in certain geographic segments have introduced near-term headwinds.
  Valuation appears attractive relative to peers, with a lower P/E and EV/EBITDA multiples. The successful integration of acquisitions and resolution of operational challenges are key catalysts for realizing potential upside.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Ingredion Inc (INGR US) - Aug 2026

<ul><li>Ingredion has entered a major new chapter with its recommended all-cash offer to acquire Tate & Lyle, a transaction valuing the U.K.-based ingredients specialist at an enterprise value of roughly £3.7 billion, or about $5 billion.</li><li>The move follows Ingredion’s multi-year push to shift its portfolio away from traditional ingredients and toward higher-value specialty solutions focused on texture, sugar reduction, nutrition, and formulation support.</li><li>Tate & Lyle brings around $2.7 billion in fiscal 2026 revenue, about $570 million in adjusted EBITDA, nearly 5,000 employees, and a patent portfolio of roughly 1,000.</li></ul>

Ingredion has entered a major new chapter with its recommended all-cash offer to acquire Tate & Lyle, a transaction valuing the U.K.-based ingredients specialist at an enterprise value of roughly £3.7 billion, or about $5 billion.The move follows Ingredion’s multi-year push to shift its portfolio away from traditional ingredients and toward higher-value specialty solutions focused on texture, sugar reduction, nutrition, and formulation support.Tate & Lyle brings around $2.7 billion in fiscal 2026 revenue, about $570 million in adjusted EBITDA, nearly 5,000 employees, and a patent portfolio of roughly 1,000.

Ingredion’s $5 Billion Tate & Lyle Takeover Could Be A Specialty Ingredients Shift!

<ul><li>Ingredion has moved to expand its functional ingredients platform with the acquisition of Benicaros, a patented prebiotic fiber made from upcycled carrot pomace and clinically shown to support immune health at extremely low daily intake levels.</li><li>The deal gives Ingredion ownership of the related intellectual property, trademarks, human clinical trials, and manufacturing know-how, making it more than a simple product bolt-on.</li><li>The timing is notable because Ingredion’s Q1 2026 results showed pressure in Food and Industrial Ingredients U.S./Canada from Argo operational issues, while Texture and Healthful Solutions delivered its eighth straight quarter of volume growth.</li></ul>

Ingredion has moved to expand its functional ingredients platform with the acquisition of Benicaros, a patented prebiotic fiber made from upcycled carrot pomace and clinically shown to support immune health at extremely low daily intake levels.The deal gives Ingredion ownership of the related intellectual property, trademarks, human clinical trials, and manufacturing know-how, making it more than a simple product bolt-on.The timing is notable because Ingredion’s Q1 2026 results showed pressure in Food and Industrial Ingredients U.S./Canada from Argo operational issues, while Texture and Healthful Solutions delivered its eighth straight quarter of volume growth.

Ingredion's Latest Acquisition May Be Its Smartest Wellness Move Yet!

<ul><li>Ingredion Incorporated reported a mixed operational and financial performance for the first quarter of 2026, reflecting both challenges and areas of resilience across its business segments.</li><li>Net sales decreased by 1% year-over-year to $1.8 billion, while adjusted operating income declined 22%, largely influenced by operational difficulties at the Argo facility in the Food and Industrial Ingredients U.S./Canada segment and softer industry volumes in both U.S./Canada and Latin America.</li><li>The Argo facility’s operational challenges were the primary detractor from company-wide performance, incurring $40 million in additional costs, significantly surpassing the earlier forecast of $10 million to $15 million.</li></ul>

Ingredion Incorporated reported a mixed operational and financial performance for the first quarter of 2026, reflecting both challenges and areas of resilience across its business segments.Net sales decreased by 1% year-over-year to $1.8 billion, while adjusted operating income declined 22%, largely influenced by operational difficulties at the Argo facility in the Food and Industrial Ingredients U.S./Canada segment and softer industry volumes in both U.S./Canada and Latin America.The Argo facility’s operational challenges were the primary detractor from company-wide performance, incurring $40 million in additional costs, significantly surpassing the earlier forecast of $10 million to $15 million.

Ingredion's $40 Million Argo Hit: Can Recovery Restore Margin Momentum?

United States

Ingredion Incorporated refines corn and produces sweeteners and starches.  The Company has customers in a wide range of industries, including the food, soft drink, brewing, pharmaceutical, corrugating, paper, and textile industries.  Ingredion has Company-owned operations, joint ventures, alliances, and technical licenses in countries around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ingredion Inc (INGR US)

Ingredion’s Big Break — Could Tate & Lyle Supercharge Its Solutions Business?

Ingredion Incorporated reported second quarter 2026 results that were broadly consistent with market expectations, marked by modest net sales...

Baptista Research

Primer: Ingredion Inc (INGR US) - Aug 2026

Ingredion is strategically shifting its portfolio towards higher-margin, value-added specialty ingredients, exemplified by the pending...

αSK Primers

Ingredion’s $5 Billion Tate & Lyle Takeover Could Be A Specialty Ingredients Shift!

Ingredion has entered a major new chapter with its recommended all-cash offer to acquire Tate & Lyle, a transaction valuing the U.K.-based...

Baptista Research

Ingredion's Latest Acquisition May Be Its Smartest Wellness Move Yet!

Ingredion has moved to expand its functional ingredients platform with the acquisition of Benicaros, a patented prebiotic fiber made from upcycled...

Baptista Research

Ingredion's $40 Million Argo Hit: Can Recovery Restore Margin Momentum?

Ingredion Incorporated reported a mixed operational and financial performance for the first quarter of 2026, reflecting both challenges and areas...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)